Tonix Pharmaceuticals Holding Corp (TNXP)

4.27
NASDAQ : Health Care
Prev Close 4.39
Day Low/High 4.18 / 4.39
52 Wk Low/High 3.30 / 37.70
Avg Volume 929.10K
Exchange NASDAQ
Shares Outstanding 7.49M
Market Cap 32.86M
EPS -15.40
Div & Yield N.A. (N.A)

Latest News

Tonix Pharmaceuticals Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder

Tonix Pharmaceuticals Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder

Registration of TNX-102 SL Could be Solely Supported by the Phase 3 HONOR Study if Topline Data are Statistically Persuasive

Tonix Pharmaceuticals To Present FDA Breakthrough Therapy-Designated PTSD Program At The MicroCap Conference

Tonix Pharmaceuticals To Present FDA Breakthrough Therapy-Designated PTSD Program At The MicroCap Conference

Phase 3 HONOR Study of TNX-102 SL in Military-Related PTSD is Enrolling

Tonix Pharmaceuticals Enrolls First Participant In Military-Related PTSD Phase 3 Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL

Tonix Pharmaceuticals Enrolls First Participant In Military-Related PTSD Phase 3 Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL

HONOR Study to Enroll 550 Participants in Approximately 35 U.S. Sites with One Unblinded Interim Analysis at Approximately 275 Participants

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL

Patent Will Provide Intellectual Property Protection until 2034 to TNX-102 SL, an FDA-Designated Breakthrough Therapy in Phase 3 Development for Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus

Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801 May Qualify for Priority Review Voucher if FDA-Approved Under Provisions in the 21st Century Cures Act

Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At NobleCon13

Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At NobleCon13

TNX-102 SL, a Phase 3 drug candidate, recently granted Breakthrough Therapy designation by the FDA; Pivotal study in military-related PTSD to begin this quarter

Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results

Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results

First Phase 3 Trial for Treatment of Military-Related Posttraumatic Stress Disorder (PTSD) Planned to Begin in First Quarter 2017

Tonix Pharmaceuticals To Present New Clinical Results From Retrospective Analysis Of Phase 2 AtEase Study In Military-Related PTSD

Tonix Pharmaceuticals To Present New Clinical Results From Retrospective Analysis Of Phase 2 AtEase Study In Military-Related PTSD

New Results to be Presented in Poster Session at International Society for Traumatic Stress Studies 32nd Annual Meeting